Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942175 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT00942175 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 160 participants.
The verdict
NCT00942175, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel, and to assess the safety of multiple doses of clopidogrel in healthy participants.
Interventions
- DRUG Clopidogrel
- DRUG Clopidogrel and Lansoprazole
- DRUG Clopidogrel and Dexlansoprazole
- DRUG Clopidogrel and Omeprazole
- DRUG Clopidogrel and Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942175
The ClinicalTrials.gov registry entry for NCT00942175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Clopidogrel is the first listed.
NCT00942175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942175 about?
NCT00942175 is a clinical study titled "A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.". The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel, and to assess the safety of multiple doses of clopido...
What is the current status of trial NCT00942175?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00942175?
The interventions under investigation include: Clopidogrel (DRUG), Clopidogrel and Lansoprazole (DRUG), Clopidogrel and Dexlansoprazole (DRUG), Clopidogrel and Omeprazole (DRUG), Clopidogrel and Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00942175?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.